Telix Pharmaceuticals Ltd has released a press release.
US Co-Promotion with EZAG for Prostate Cancer Imaging
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Telix Pharmaceuticals
- TLX66 Meets Study Objectives in Patients with AL Amyloidosis
- German Distribution Agreement with Eckert and Ziegler
- Phase III Prostate Cancer Therapy Clinical Trial Commences
- Activities Report and App 4C for quarter ended 31 March 2021
- Japanese Renal Cancer Imaging Trial Meets Study Objectives
Later from Telix Pharmaceuticals
- Update on FDA New Drug Application Review for Illuccix
- TLX101 for Glioblastoma Therapy - Clinical Trial Update
- ZIRCON Phase 3 Renal Cancer Imaging Study - Progress Update
- App 4C and Activities Report for June 2021 Quarter
- Telix Seneffe Production Facility - Progress Update
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals